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Abstract
Background: CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of
E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under
genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2
for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this
switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under
genotoxic stress and observed subsequent DNA damage and repair mechanisms.
Results: We found that R-Roscovitine alone was unable to alter cyclin A1 transcriptional levels, however it was able
to reduce protein expression through a proteosome-dependent mechanism. When combined with DNA damaging
agents, R-Roscovitine was able to prevent the DNA damage-induced upregulation of cyclin A1 on a transcriptional
and post-transcriptional level. This, moreover resulted in a significant decrease in non-homologous end-joining
(NHEJ) paired with an increase in DNA DSBs and overall DNA damage over time. Furthermore, microarray analysis
demonstrated that R-Roscovitine affected DNA repair mechanisms in a more global fashion.
Conclusions: Our data reveal a new mechanism of action for R-Roscovitine on DNA repair through the inhibition
of the molecular switch between cyclin A family members under genotoxic conditions resulting in reduced NHEJ
capability.
Background
The cell cycle is comprised of a series of highly coordi-
nated events culminating in cell growth and division.
Cyclin-dependent kinases (CDK) and their cyclin coun-
terparts strictly regulate and drive cell cycle progression
and different CDK/cyclin complexes are responsible for
the timely occurrence of each phase transition in order
to maintain genetic integrity throughout generations.
Cancer cells have been frequently found to have a de-
regulated CDK activity allowing them to escape the nor-
mal cell cycle and proliferate uncontrollably. For these
reasons CDKs have been considered attractive targets
for cancer therapy and several CDK-inhibitors have
been developed and are under intense investigation[1].
R-Roscovitine (Seliciclib, CYC202; herein referred to
as Roscovitine), one of the most promising members of
the CDK-inhibitor family, is an orally available adeno-
sine analogue prominently targeting CDK2 (also affect-
ing CDKs 1, 7 and 9 at a much lower rate)[2] with a
low off-target effect on other members of the human
kinome[3], and a nice toxicity profile[4]. In preclinical
s t u d i e sR o s c o v i t i n eh a ss h o w ns i g n i f i c a n tin vitro and
in vivo antitumor activity on a wide panel of human
cancers and is currently in phase II clinical trials[5].
Since preclinical experimentation, it has become evident
that, CDK-inhibitors, such as Roscovitine, may actually
curb the activity of DNA repair machinery[6,7], hence
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ciation with either radiation therapy[8,9] or genotoxic
agent-based chemotherapy[10]. However, the mechan-
ism of this inhibition is still elusive.
One of the proposed means for CDK-inhibitors to
affect DNA repair is through checkpoint deregulation
[11-13], but increasing evidence supports a complex net-
work of direct interactions between individual CDKs
and proteins that play a key role in DNA damage repair
(DDR). It is known that different DNA repair pathways
are preferentially activated at specific stages of the cell
cycle possibly suggesting a functional crosstalk between
CDK/cyclin complexes and DNA repair mechanisms
[14]. In particular, CDK2 has been shown to interact
with p53[15], BRCA1[16], BRCA2[17], Ku70[18] and
both, CDK1 and CDK2, can modulate BRCA1-BARD1
activity[13,19]. Moreover, CDK2 knock-down cells have
an attenuated capacity to repair DNA damage suggest-
ing a pivotal role for CDK2[7] in DDR. Given the ability
of CDKs to compensate for each other in vivo,o v e r a l l
CDK activity has been proposed to be influential in
DDR regulation[20] however CDK2 function seems to
have a specific role in some survival pathways[21].
Cyclins, similarly to CDKs, have been correlated to
DDR. Cyclin E levels are upregulated under genotoxic
stress conditions[22] and a post-translational cleavage
generates an 18-amino acid peptide, which has been
shown to interact with Ku70[18] promoting the release
of the pro-apoptotic factor Bax from the inactivating
complex Bax/Ku70. Moreover, an increasing amount of
data suggests an important role in DDR for the A-type
cyclins, and in particular for cyclin A1. Differing from
cyclin A2, ubiquitously expressed during the S and G2/
M phases of the cell cycle, cyclin A1 is a testis-specific
cyclin, which interacts with CDK2 and is involved in
germ cell meiosis and spermatogenesis[23]. Cyclin A1
may have a role in carcinogenesis, as it has been found
to be over-expressed in acute myeloid leukemia and var-
ious other tumour types[23-25], however, its role in can-
cer is still particularly obscure. In somatic non-testicular
tissues, cyclin A1 is not expressed or is expressed at
very low basal levels. After genotoxic insult, cyclin A1
mRNA is upregulated in vitro[26] and in vivo[27]. At a
molecular level, human CDK2/cyclin A1 complexes
interact with members of the Ku family and phosphory-
late Ku70[27,28], a pivotal player in the non-homolo-
gous end-joining (NHEJ) double strand break (DSB)
repair pathway. Furthermore, under genotoxic condi-
tions the kinase activity of CDK2/cyclin A1 complex
increases, while the relative kinase activity of CDK2/
cyclin A2 decreases and the CDK2/cyclin A1 complex
out-competes with CDK2/cyclin A2 for Ku70 binding
[28]. Moreover, it has recently been found that CDK2
phosphorylation status and structure changes upon the
cyclin A family member with which it is bound [29]
suggesting a non-redundant function between CDK2/
cyclin A1 and CDK2/cyclin A2 complexes. Finally cyclin
A1 knockout mice and Xenopus embryos exhibited a
clear defect in DNA repair[27,30] and are more prone
to undergo apoptosis[31].
Taken together these data support that during geno-
toxic stress differential transcriptional levels and activity
of cyclin A family members may redirect CDK2 toward
DNA repair resulting in a modulation of NHEJ. Since
one of the most relevant effects of CDK inhibitors is the
downregulation of cell cycle related cyclins, we investi-
gated if the inhibition of DNA repair mechanisms by
Roscovitine may also occur through the modulation of
the expression levels of cyclin A family members. Phy-
siological CDK-inhibition, in fact, results in cyclin
downregulation through the inhibition of E2F-family
transcription factors, which drive and regulate cell cycle-
related cyclin transcription. Given that the promoter of
the cyclin A1 gene, CCNA1, is different from the other
cell cycle-related cyclins, not being under the regulation
of E2Fs[32], here we analyzed the effects of Roscovitine
on cyclin A1 expression and modulation of DNA repair
mechanisms. We demonstrated that under DNA dama-
ging conditions cyclin A1 is strongly upregulated and
localizes to the nucleus. Although Roscovitine alone was
not sufficient to reduce the basal levels of cyclin A1, in
contrast to cell cycle related cyclins, Roscovitine treat-
ment could abolish the DNA damage-induced cyclin A1
upregulation, reducing NHEJ and significantly hindering
DNA repair over time.
Results
DNA damage induces a switch in the respective levels of
A-family cyclins
We first compared mRNA levels of both members of
the cyclin A family after treatment with increasing doses
of Doxorubicin (from 250 nM up to 5 μM), a well-
known inducer of DNA DSBs. We found that cyclin A1
upregulation is dose dependent with a plateau that is
reached around 2.5 μM (IC90). On the contrary, Doxor-
ubicin treatment caused a downregulation of cyclin A2
mRNA levels with a nadir that is reached at the dose of
750 nM (IC50) followed by a relative increase close to
basal levels (that are not reached) at a dose of 2.5 μM
(IC90) and further followed by a constant decline at
higher doses (Figure 1A).
These finding were congruent with protein levels of
both cyclins A1 and A2 (Figure 1B). The cyclin A1 anti-
body we utilized detected two bands, which both aug-
mented upon treatment. The upper band we
hypothesized to be a phosphorylated or hyper-phos-
phorylated form of cyclin A1, which was barely detect-
able when phosphatase inhibitors were excluded from
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or non-phosphorylated form, which was detectable
when cell lysis was performed with or without phospha-
tase inhibitors (Additional File 1). Relative quantification
of bands showed that Doxorubicin, while inducing a
slight increase in the hyper-phosphorylated form of
cyclin A1, induced a marked dose-dependent increase in
the hypo-phosphorylated form. These finding were also
noted in A549 cells 1 hour after gamma-irradiation
(Figure 1C) suggesting that cyclin A1 upregulation is
Figure 1 DNA DSBs induce an upregulation of cyclin A1 but not cyclin A2 in A549 cells in a cell cycle-independent manner A) Relative
expression levels respect to GAPDH (2^
-ΔCt) of cyclin A1 (CCNA1) vs. cyclin A2 (CCNA2) mRNA after 24 hours of treatment with
increasing doses of Doxorubicin (250 nM to 5 μM). B) Western blot analysis of cyclin A1, cyclin A2, CDK1 and CDK2 expression levels with
Hsp70 as a loading control after 24 hours of treatment with Doxorubicin (Dox 750 nM and 2.5 μM). Quantification of cyclin A1 expression levels
as normalized pixel area respect to Hsp70. C)Western blot analysis of protein expression 1 hour after administration of increasing doses of g-
irradiation (4 Gy to 32 Gy). D) Flow cytometry cell cycle analysis with corresponding western blot showing cyclin A1, cyclin A2, CDK1 and CDK2
expression levels over the course of the synchronous cell cycle induced by serum starvation.
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ing of its upregulation is compatible with DNA repair
events.
To ensure that the increase in cyclin A1 expression
observed was not a result of cell cycle redistribution, we
analyzed the expression of cyclin A family members
during the synchronous cell cycle in the A549 NSCLC
cell line. We observed that unlike cyclin A2, which, as
expected, was expressed during the S and G2/M phases,
cyclin A1 remained fairly constant throughout the cell
cycle (Figure 1D). Cell cycle analysis by flow cytometry
was also performed on asynchronous A549 cells treated
for 24 hours with Doxorubicin (750 nM and 2.5 μM) in
comparison to untreated controls, and as expected Dox-
orubicin treatment resulted in an activation of DNA
damage cell cycle checkpoints at G1-S and G2-M phase
transitions (Additional File 2). Cells treated with 750
nM Doxorubicin exhibited a decrease in the percentage
of cells in S phase, which is duly noted by the observed
decrease in cyclin A2 expression levels. However, treat-
ment with 2.5 μM Doxorubicin resulted in a relative
increase in the percentage of cells in S phase, which
mirrors the increase in cyclin A2 expression at higher
doses of Doxorubicin as seen by western blot. These
data confirm that cyclin A1 is strongly induced under
DNA damaging conditions and also supports a DNA
damage-induced molecular switch between cyclin A2
and cyclin A1 during genotoxic stress.
Cyclin A1 localizes to the nucleus during genotoxic
conditions and its overexpression increases in vitro NHEJ
activity
To determine if cyclin A1 upregulation under DNA
damaging conditions was specific to a sub-population or
was found in all cells we performed flow cytometry ana-
lysis of Doxorubicin treated A549 cells. Cyclin A1 upre-
gulation was observed in all cells, further confirming
that this was independent of the cell cycle (data not
s h o w n ) .W ea l s oa n a l y z e dD oxorubicin treated A549
cells by immunofluorescence staining and microscopy
noting not only a dose-dependent increase in fluores-
cent signal but also a nuclear localization of cyclin A1
protein at higher doses of Doxorubicin (2.5 μM) treat-
ment (Figure 2A). The nuclear localization and the
dose-dependent increase in cyclin A1 expression could
speak further towards a specific role for cyclin A1 in
DNA repair mechanisms.
To address the role of cyclin A1 in DNA DSB repair
mechanisms, we used an in vitro plasmid re-ligation
assay based on the ability of the whole cellular extract
to re-join a linearized plasmid. Wortmannin, a known
inhibitor of DNA dependent protein kinase (DNA PK),
was used as a control to demonstrate the dependency of
re-ligation upon NHEJ. Quantification of plasmid re-
ligation was performed by real-time PCR utilizing pri-
mers, which bound both upstream and downstream of
the enzymatic cut site, amplifying only upon re-ligation
of plasmid DNA, and values were normalized on the
quantity of plasmid in each reaction by primers which
bound an intact region of plasmid DNA. We analyzed
the NHEJ capability of HEK293FT cells (utilized for
their optimal transfection efficiency), transiently trans-
fected to overexpress cyclin A1 or enhanced yellow
fluorescent protein (YFP, negative control). In cells over-
expressing cyclin A1 there was a significant increase
(approximately 6-fold) in NHEJ activity respect to YFP
controls (Figure 2B).
Roscovitine, at doses primarily inhibiting CDK2, but not
CDK7 or 9 prevents DNA damage-induced cyclin A1
transcriptional upregulation and increases protein
degradation
Roscovitine, being a CDK2 inhibitor, can depress E2F-
dependent transcription by blocking the phosphorylation
of Rb-family proteins. Cyclin A1 expression is not E2F-
dependent[30], therefore we investigated the effects of
Roscovitine on cyclin A1 basal expression and eventually
on the DNA damage-induced upregulation. First we
analyzed the mRNA expression levels of cyclins A1, A2,
B, D, and E after 24 hours of incubation with increasing
doses (up to 60 μM) of Roscovitine. We found that all
cyclin mRNA expression levels were greatly reduced
respect to untreated controls (Figure 3A), except for
cyclin A1, whose basal levels were substantially lower
than the other cyclins and were not downregulated but
remained fairly constant upon Roscovitine treatment
consistent with its E2F-independent transcriptional reg-
ulation (Figure 3A). Therefore, we treated A549 cells for
24 hours with increasing doses of Doxorubicin (as pre-
viously stated) alone or in combination with a fixed
dose of 20 μM Roscovitine. We chose to use the dose of
20 μM as it is not only a dose commonly utilized in the
literature but also as it was experimentally proven to
preferentially inhibit CDK2 resulting in a hypo-phos-
phorylation of p130/Rb2, while it is the highest dose
with a limited effect on CDK7 and CDK9, as shown by
the phosphorylation of the C-terminal domain (CTD) of
RNA Polymerase II on serine 5 and 2 respectively (Fig-
ure 3B). Roscovitine was able to completely abolish the
Doxorubicin-induced cyclin A1 mRNA and protein
upregulation (Figure 3C&3D)s u g g e s t i n gt h a tar e s i d u a l
CDK2 activity is required for cyclin A1 upregulation.
Furthermore, co-administration of Doxorubicin and
Roscovitine resulted in a change in cyclins A2, B, D and
E mRNA expression levels, respect to Doxorubicin treat-
ment alone (Additional File 3). In particular, cyclin A2
mRNA levels demonstrated an attenuated variation dur-
ing combination treatments, which is consistent with
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(Additional File 2). At the protein level, the combination
of Roscovitine with Doxorubicin resulted in an inversion
of the Doxorubicin-induced molecular switch between
cyclin A1 and cyclin A2 (Figure 3D).
Unlike cyclin A1 mRNA levels, treatment with Ros-
covitine alone also resulted in a decrease in cyclin A1
protein expression over time (Figure 3D&3E), suggest-
ing that, aside from transcriptional regulation, Roscov-
itine may also regulate cyclin A1 on a post-
transcriptional level. To confirm this hypothesis we
treated A549 cells with Doxorubicin and Roscovitine
respectively as well as 10 μM of the proteosome inhibi-
tor MG-132. Inclusion of MG-132 significantly
prevented the downregulation of cyclin A1 protein
levels after treatment with 20 μMR o s c o v i t i n e( F i g u r e
3E). The transcriptional and post-transcriptional regula-
tion of cyclin A1 by Roscovitine was confirmed in a
p a n e lo fN S C L C( A 5 4 9a n dH 2 3 ) ,b r e a s t( M C F - 7a n d
MDA-MB-231) and prostate cancer (LNCAP and
DU145) cell lines (data not shown).
Combined treatment with Roscovitine and Doxorubicin
results in a downregulation of NHEJ capability
Cyclin A1 knockout MEFs have shown a reduced
NHEJ capability[27]. To determine if Roscovitine may
have a comparable effect on NHEJ mechanisms, we
incubated untreated A549 cell lysates with 20 μM
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Figure 2 Nuclearization of cyclin A1 under DNA DSB conditions and its role in NHEJ. A) Immuno-fluorescence analysis by fluorescent
microscopy of cyclin A1 localization in A549 cells after treatment with Doxorubicin (750 nM and 2.5 μM). Lower panels show FITC-stained cyclin
A1 expression (green) and upper panels show FITC and DAPI (blue) merge at 400× magnification. B) Fold change, respect to YFP, of in vitro
NHEJ plasmid re-ligation activity as quantified by real time PCR in HEK293FT cells transiently transfected with YFP (control) or cyclin A1 (CCNA1)
and respective western blot and ponceau S staining verifying overexpression respect to Hsp70.
Federico et al. Molecular Cancer 2010, 9:208
http://www.molecular-cancer.com/content/9/1/208
Page 5 of 14Figure 3 Roscovitine inhibits DNA DSB-induced upregulation of cyclin A1 mRNA at doses primarily affecting CDK2 and post-
translationally downregulates cyclin A1 protein levels over time in A549 cells. A) Expression levels respect to GAPDH (2^
-ΔCt), in mRNA of
cyclin A1, cyclin A2, cyclin B, cyclin D and cyclin E after 24 hours of treatment with increasing doses of Roscovitine (5-60 μM). B) (Upper blot)
Western blot analysis of inhibitory activity of Roscovitine (Rosc) against CKD2 phosphorylation of p130/Rb2 as shown by a shift in p130/Rb2
band height from hyper-phosphorylated in control cells to hypo-phosphorylated in Roscovitine treated cells, upper band is non-specific. (Lower
blot) Western blot analysis of Roscovitine inhibition of CDK7 and CDK9 phosphorylation of the C-terminal domain (CTD) of RNA polymerase II,
on serine 5 and serine 2 respectively, in cells treated for 24 hours with increasing doses of Roscovitine (10-40 μM). C) Fold change, respect to
control (2^
-ΔΔCt), of cyclin A1 mRNA expression levels in cells treated with either increasing doses of Doxorubicin alone (250 nM to 5 μM) or
increasing doses of Doxorubicin in combination with 20 μM Roscovitine for 24 hours. Note that black bars represent Doxorubicin only treated
cells and correspond to the vertical axis on the left-hand side of the graph, while grey bars represent Doxorubicin and Roscovitine treated cells
and correspond to the vertical axis on the right-hand side of the graph. D) Western blot analysis of cyclin A1, cyclin A2, CDK1 and CDK2 protein
expression in cells treated for 24 hours with either Doxorubicin (750 nM or 2.5 μM) alone, 20 μM Roscovitine alone, or in combination (Dox 750
nM/2.5 μM + R). p53 protein expression was included as a control for drug treatments. E) Post-translational inhibition of cyclin A1 protein levels
over time. (Left-side blot) cyclin A1 and p53 protein expression in cells treated for increasing amounts of time (6-72 hours) with 20 μM
Roscovitine. (Right-side blot) cyclin A1 and p53 expression in cells treated for 24 hours with either Doxorubicin (750 nM and 2.5 μM) or 20 μM
Roscovitine alone or in combination with 10 μM of the proteosome inhibitor MG-132.
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prior to incubation with linearized plasmid. While
Wortmannin was able to almost completely inhibit
NHEJ activity, DMSO had no effect and Roscovitine
resulted in an approximate 25% diminution in plasmid
re-ligation, which can be accounted for by a direct
inhibition of CDK activity and eventual off-target
effects of the drug (Figure 4A). However, when lysates
from A549 cells treated for 12 hours with 20 μM
Roscovitine were assayed for NHEJ capability, they
demonstrated an approximate 45% reduction in plas-
mid re-ligation (Figure 4B) as a result of an additional
biological mechanism to the pharmacological inhibition
of CDK2.
Roscovitine enhances Doxorubicin-induced DSBs and
delays DNA damage repair over time
To determine if the inhibition of NHEJ activity led to an
overall increase in DNA DSBs we analyzed the quantity
of phosphorylated gH2AX by western blot (Figure 5A).
After six hours of incubation with respective drug treat-
ments, we removed the drug-containing medium and
analyzed A549 cells for gH2AX phosphorylation imme-
diately following the six hour treatment(t0), then six(t6)
and 24(t24) hours after drug removal with respect to
control cells. Doxorubicin treatment induced an activa-
tion of gH2AX, which was significantly augmented
following combined treatment with Roscovitine over
time (Figure 5A), even though Roscovitine alone did not
significantly activate gH2AX as shown by western blot
and immunofluorescence staining (Figure 5A&5B).
In addition to gH2AX, we observed overall DNA
damage on a single-cell level utilizing the alkaline comet
assay. The comet assay revealed no significant differ-
ences in DNA damage between cells treated with only
Doxorubicin and those treated with both Doxorubicin
and Roscovitine six hours-post drug removal. However,
24 hours after drug removal, while Doxorubicin-only
treated cells had completely repaired the damage, cells
treated with both Doxorubicin and Roscovitine con-
tained a greater amount of DNA damage (p ≤ 0.0001)
(Figure 5C&5D). These data further support the hypoth-
esis that Roscovitine can augment Doxorubicin-induced
DNA damage by hindering DSB repair over time.
Combined treatment leads to global changes in DNA
repair pathways
To assess the global effects of combination treatment,
we performed genome-wide microarray analysis on
cRNA from A549 cells treated for 24 hours with either
1 μM Doxorubicin alone or in combination with 20 μM
Roscovitine. Here we focus our analysis primarily on
genes involved in the DNA repair pathways: mismatch
repair (MMR), nucleotide excision repair (NER), homo-
logous recombination (HR), and NHEJ. We grouped the
genes related to these pathways that changed in a statis-
tically significant manner (p-value ≤ 0.05) after combi-
nation treatment respect to Doxorubicin treatment in
Table 1 and Figure 6. The most significant changes
were observed in the NHEJ and HR pathways. In parti-
cular in HR we observed a decrease in BRCA1 (fold
change: -0.46) and RAD50 (-0.75). Furthermore, there
were significant variations in key genes involved in
NHEJ. In particular, we observed a significant decrease
in the expression levels of Ku80 (XRCC5 -0.61), DNA-
activated protein kinase (PRKDC -0.61), and NHEJ1
(-0.80) (Table 1 and Figure 6). These data support the
reduced NHEJ activity observed with the in vitro NHEJ
plasmid re-ligation assay. Moreover, they demonstrate a
Figure 4 Roscovitine inhibits NHEJ activity synergistically when
combined with Doxorubicin treatment in A549 cells. A) Analysis
by real time PCR of NHEJ plasmid re-ligation activity of untreated
A549 cell lysate with the addition of 20 μM Roscovitine, DMSO or
Wortmannin. B) Analysis by real time PCR of NHEJ plasmid re-
ligation activity in A549 cells treated for 12 hours with 20 μM
Roscovitine. Wortmannin was added to untreated cell lysate as a
negative control for NHEJ activity in vitro.
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Page 7 of 14Figure 5 Roscovitine when combined with Doxorubicin increases DNA DSBs and overall DNA damage over time in A549 cells.
A) Western blot analysis of DNA DSBs by phosphorylated gH2AX (serine 139) immediately (t0) or 6 (t6) and 24 (t24) hours following a 6 hour
treatment with either 750 nM Doxorubicin (D) or 20 μM Roscovitine alone or in combination (DR). B) Immunofluorescence analysis by
fluorescent microscopy of phosphorylated gH2AX (serine 139) at the abovementioned time points following 6 hours of treatment with 20 μM
Roscovitine or 2.5 μM Doxorubicin (as a positive control for DSBs). Images shown are gH2AX (FITC) and DAPI merges under 100× (upper panels)
and 400× (lower panels) magnifications. C) Alkaline comet assay quantification and D) respective images (400x magnification), 6 (t6) and 24 (t24)
hours following a 6 hour incubation with abovementioned treatments (Control, NT; Doxorubicin, D; Doxorubicin + Roscovitine, D+R; Roscovitine,
R) to measure overall DNA damage.
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of combination treatment with Roscovitine.
Discussion
Under genotoxic conditions the CDK2/cyclin A1 com-
plex increases its functional kinase activity and the abil-
i t yt op h o s p h o r y l a t eK u 7 0 .I na d d i t i o n ,h e r ew e
demonstrated upon treatment with different DNA
damaging agents (doxorubicin or g-irradiation) a marked
dose dependent increase in the RNA and protein levels
of cyclin A1, which is independent of cell cycle phase
redistribution. Conversely cyclin A2 (whose expression
is tightly related to the S and G2-M phases of the cell
cycle) is downregulated under genotoxic stress condi-
tions as a result of the check-point activation and
Table 1 Statistically significant genes involved in DDR
after combination treatment
ID
AFFYMETRIX
Gene
symbol
A549
D1
A549
D2
A549
DR1
A549
DR2
M P.Value
Signal
223598_at RAD23B 8.83 8.91 7.68 7.88 -1.09 0.000223
202996_at POLD4 10.01 10.14 8.89 9.29 -0.98 0.001349
209084_s_at RFC1 5.67 5.77 4.87 4.76 -0.90 0.000436
219418_at NHEJ1 6.76 6.55 5.75 5.96 -0.80 0.001689
211450_s_at MSH6 8.46 8.47 7.61 7.76 -0.78 0.001138
209349_at RAD50 6.40 6.48 5.63 5.75 -0.75 0.001394
203720_s_at ERCC1 9.57 9.65 8.78 8.98 -0.73 0.002189
205887_x_at MSH3 5.71 5.56 5.03 4.85 -0.69 0.003738
219715_s_at TDP1 7.94 7.81 7.26 7.12 -0.68 0.002669
210543_s_at PRKDC 8.36 8.36 7.78 7.72 -0.61 0.00473
208643_s_at XRCC5
(Ku80)
9.94 10.06 9.31 9.46 -0.61 0.00434
213734_at RFC5 7.64 7.37 6.91 7.03 -0.53 0.014248
212525_s_at H2AFX 6.05 6.17 5.51 5.69 -0.51 0.011937
211851_x_at BRCA1 5.84 5.93 5.39 5.46 -0.46 0.022329
204752_x_at PARP2 7.89 7.95 7.50 7.65 -0.34 0.049
205672_at XPA 7.63 7.54 7.89 7.87 0.29 0.03678
221143_at RPA4 3.79 4.06 4.25 4.26 0.33 0.01878
1053_at RFC2 6.83 6.61 7.05 7.07 0.34 0.049
227766_at LIG4 5.56 5.40 6.11 5.88 0.52 0.025825
202176_at ERCC3 7.84 7.70 8.31 8.30 0.54 0.006878
209903_s_at ATR 8.11 7.93 8.64 8.53 0.57 0.009919
202451_at GTF2H1 8.60 8.55 9.29 9.07 0.61 0.01218
232134_at POLS 6.32 6.00 6.98 6.75 0.71 0.008367
231119_at RFC3 4.31 4.56 4.95 5.35 0.72 0.008497
204023_at RFC4 7.26 7.17 8.04 7.84 0.72 0.00282
222233_s_at DCLRE1C 5.50 5.44 6.41 6.10 0.78 0.00239
213468_at ERCC2 5.82 5.85 6.58 6.64 0.78 0.000828
209805_at PMS2 6.67 6.74 7.56 7.43 0.79 0.000908
209805_at PMS2 6.67 6.74 7.56 7.43 0.79 0.000908
1554743_x_at PMS1 4.32 4.51 5.29 5.16 0.81 0.002444
204838_s_at MLH3 7.13 7.05 7.97 7.86 0.83 0.001711
Genes involved in DNA repair mechanisms, those shown either decreased or
increased in expression level (p value ≤ 0.05) after combination treatment
with 1 μM Doxorubicin and 20 μM Roscovitine as compared to 1 μM
Doxorubicin only, in A549 cells after 24 hours of treatment.
Figure 6 Combination treatment with Roscovitine globally
affects DNA repair pathways. Corrected microarray signal values
of genes involved in DNA repair clustered by specific DNA repair
pathway of A549 cells treated for 24 hours with 1 μM Doxorubicin
alone or in combination with 20 μM Roscovitine in comparison to
control cells.
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Page 9 of 14consequent decrease of the S phase fraction. This switch
in the respective levels of the A-family cyclins may be
functionally relevant to redirect CDK2 activity toward
DNA repair, especially given the findings that the ecto-
pic overexpression of cyclin A1 increased in-vitro NHEJ
activity and that cyclin A1 depletion, as demonstrated
by others[27], results in an impaired DNA DSB repair
ability.
DNA DSBs are considered the most lethal form of
DNA damage and CDK inhibition has been shown to
potentially affect the two major DSB repair pathways
(HR and NHEJ)[7]. Various mechanisms have been pro-
posed to explain this effect such as the deregulation of
the DNA damage-induced checkpoint signalling cascade
[13] or the downregulation of specific genes involved
[33,34]. Roscovitine is an oral 2,6,9 trisubstituted purine
analog currently under phase II investigation, which
competes with ATP for the catalytic binding site on
CDK2 (but also CDKs 1, 7 and 9 with a much lower
affinity) with a demonstrated antitumor activity in many
human cancer models and a nice toxicity profile.
One of the most prominent effects of the drug is the
inhibition of CDK2/cyclin E complexes, which causes a
decrease in Rb phosphorylation and a consequent inacti-
vation of E2F family members, thus leading to cyclin
transcriptional downregulation and ultimately to cell
cycle arrest. This strong transcriptional depression of
most of the cell cycle related cyclins further enforces
the drug’s inhibitory effect on CDK/cyclin complexes.
Furthermore, Roscovitine has been shown to downregu-
late several other genes involved in a wide spectrum of
cellular functions[35,36], probably as a result of partial
CDK7/cyclin H and CDK9/cyclin T inhibition[37]. In
addition, whole genome ChIP-on-chip analysis recently
mapped E2F transcription factor family members to the
promoters of many more genes than were traditionally
associated with the cell cycle[38], suggesting an alterna-
tive mechanism to explain these transcriptional effects.
We investigated the effects that Roscovitine may have
on cyclin A1 transcription as one of the possible
mechanisms through which CDK2 inhibition may curb
DNA DSB repair activity. The promoter of the cyclin
A1 gene, CCNA1 is not E2F-dependent and, consis-
tently, increasing doses of Roscovitine did not repress
cyclin A1 basal transcription levels in contrast to cyclins
A2, B, D and E. However, we demonstrated that Roscov-
itine at doses preferentially inhibiting CDK2 but not
CDK7 and 9 completely abolished cyclin A1 DNA
damage-induced upregulation, thus suggesting that resi-
dual CDK2 activity is required for cyclin A1 upregula-
tion. In addition Roscovitine co-administered with
doxorubicin was able to largely modify the patterns of
cell cycle phase distribution in comparison to doxorubi-
cin only treatment. This resulted in an augmented S
phase and consequently in an increased expression of
cyclin A2. The combined treatment thus resulted in the
complete inversion of the doxorubicin-induced switch
between cyclin A1 and cyclin A2.
Roscovitine, alone or under DNA damaging condi-
tions, was able to diminish cyclin A1 protein levels as
well. Such transcriptional and post-transcriptional
repression was observed in different NSCLC, prostate
and breast cancer cell lines and we propose that this
potentiates and synergizes the Roscovitine-mediated
CDK2 inhibition thus resulting in a significant decrease
of cellular NHEJ ability. In fact, we observed that combi-
nation treatment led to an increase in DNA DSBs and
overall DNA damage over-time, further substantiating,
not only the importance of CDK-inhibitors in combina-
tion therapy but also the role of CDKs in DNA repair
mechanisms. While these findings were supported by
genome-wide mircroarray analysis, we also observed a
significant effect on key genes involved in other DNA
repair pathways.
Conclusions
Roscovitine has shown to be able to significantly modify
the DDR response. Even considering the many genes
that are potentially involved, the putative role of CDK2
in multiple DDR pathways along with the downregula-
tion of cyclin A1, may further explain the effective inhi-
bition of a broad range of DNA repair mechanisms by
Roscovitine. In particular since NHEJ is considered the
major pathway for the repair of gIR-induced DNA DSBs
in human cells[39], we believe our data support further
investigation on the therapeutic advantages of combina-
tion therapy with Roscovitine and Radiotherapy.
Methods
Cell Culture and Serum Starvation
The following solid cancer human cell lines were pur-
chased from and authenticated by American Type Cul-
ture Collection (ATCC; Manassas, VA) and cultured at
37°C in a humidified atmosphere of 5% CO2 in air,
within the appropriate medium according to supplier
recommendations supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (Atlanta Biologicals; Law-
renceville, GA) and 100U of Penicillin and 100 μg/ml of
Streptomycin (Sigma-Aldri c h ;S t .L o u i s ,M O ) :N S C L C
cell lines A549 and H23, breast cancer cell lines MCF-7
and MDA-MB-231, prostate cancer cell lines LNCAP
and DU145, and the adenovirus transformed human
embryonic kidney epithelial cells HEK293FT. Cells were
regularly sub-cultured according to ATCC recommen-
dations with a 0.25% trypsin-EDTA solution (Sigma). To
obtain synchronous populations of cells, confluent plates
of A549 cells were incubated in media supplemented
with 0.1% (v/v) heat-inactivated fetal bovine serum for
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Page 10 of 1496 hours. Cells were then sub-cultured into serum-con-
taining medium and time points were taken every four
hours.
Drugs, irradiations and treatments
Doxorubicin was obtained from BioMol International
(Plymouth Meeting, PA). Lyopholized drug was re-sus-
pended into a 1:1 mixture of dimethyl sulfoxide
(DMSO; Fisher Scientific; Pittsburgh, PA) and MilliQ fil-
tered H2O (Millipore; Bellerica, MA) to a concentration
of 4.31 mM, aliquoted for use and stored at -20°C. Ros-
covitine was obtained from Signa Gen Laboratories
(Gaithersburg, MD). Lyophilized drug was re-suspended
into DMSO to a concentration of 14.1 mM, aliquoted
and stored at -20°C until use. Fresh dilutions from the
stock solutions were prepared for each treatment. Taxol
w a so b t a i n e df r o mU S BC o r p oration (Cleveland, OH).
Lyophilized drug was re-suspended into DMSO to a
concentration of 5.86 mM, aliquoted and stored at -20°
C until use. MG-132 (Z-Leu-Leu-Leu-al) was obtained
from Sigma. Lyophilized drug was re-suspended into
DMSO to a concentration of 10 mg/ml, aliquoted and
stored at -20°C until use. Irradiations were performed in
an AECL Gamma Cell 40, Cs-137 irradiator at a dose
rate of 1 Gy/minute for respective doses. In treatments
throughout this article the control samples refer to cells
treated with an equal concentration (v/v) of DMSO as
in the highest drug concentration used per experiment.
Western Blot Analysis and SDS-PAGE
Equal amounts (50-100 μg) of whole cell lysates were
resolved by SDS-PAGE and transferred to a nitrocellu-
lose membrane (Whatman Inc., Piscataway, NJ) by wet
electrophoretic transfer. Non-specific binding sites were
blocked for 1 hour at room temperature with 3% non
fat dry milk (NFM) in tris-buffered saline containing
0.01% Tween-20 (TBS-T) and probed with the following
primary antibodies in 3% NFM in TBS-T overnight at 4°
C; rabbit anti-cyclin A1 (sc-15383; Santa Cruz Biotech-
nology Inc.; Santa Cruz, CA), mouse anti-cyclin A2
(CY-A1; Sigma), mouse anti-cdc2 (A17; Abcam, Cam-
b r i d g e ,M A ) ,r a b b i ta n t i - C D K 2( s c - 1 6 3 ;S a n t aC r u z ) ,
rabbit anti-p53 (sc-6243; Santa Cruz), mouse anti-Hsp70
(sc-24; Santa Cruz), mouse anti-p130/Rb2 full length
(610262; BD Biosciences, San Jose, CA), rabbit anti-ser-
ine 952 phosphorylated p130/Rb2 (sc-16298; Santa
Cruz), rabbit anti-serine-2 phosphorylated RNA poly-
merase II (A300-654A; Bethyl Laboratories Inc., Mon-
tgomery, TX), rabbit anti-serine-5 phosphorylated RNA
polymerase II (A300-655A; Bethyl), mouse anti-a-tubu-
lin (sc-58666; Santa Cruz), and mouse anti-ser139 phos-
phorylated histone gH2AX (Millipore cat. #05636; lot#
DAM1567248). Membranes were washed for 15 minutes
in TBS-T and then incubated for 1 hour with either
goat anti-mouse (31432; Pierce; Rockford, IL) or mouse
anti-rabbit (31464; Pierce) horseradish peroxidase conju-
gated IgG at a dilution of 1:10,000 in 3% NFM in TBS-
T. This was followed by 15 minutes of wash in TBS-T
and enhanced chemiluminescence (ECL; Amersham,
Buckinghamshire, UK) according to the manufacturer’s
instructions. All western blot images included in article
are representative of at least three consecutive indepen-
dent experiments.
Immunostaining
Following respective drug treatments, cells grown
directly on sterilized glass coverslips were fixed and per-
meabilized for 10 minutes in 70% cold methanol
(MeOH), immunostained (for cyclin A1 and gH2AX)
and analyzed as previously described[40].
Flow cytometry
Cells (1 × 10
6) were collected, after respective drug
treatments, washed, resuspended in 1 ml of PBS and
fixed and permeabilized for at least 10 minutes in 70%
cold ethanol. After fixation cells were pelleted, washed 3
times with PBS, re-suspended into a primary antibody
solution (10 μg/ml antibody diluted in PBS) and incu-
bated on ice for 15 minutes. Cells were then pelleted,
washed 3 times with PBS, re-suspended into FITC-con-
jugated secondary antibody solution (10 μg/ml) and
incubated for 15 minutes on ice protected from the
light. Cells were washed 3 times in PBS and re-sus-
pended in propidium iodide staining solution, 10 μg/ml
propidium iodide (from stock of 0.5 mg/ml in 0.38 mM
sodium citrate pH 7.0) and 25 μg/ml DNase-free RNase
A (from stock of 10 mg/ml RNase A in 10 mM Tris pH
7.5 and 15 mM NaCl) diluted in PBS. Cells were incu-
b a t e da t3 7 ° Cf o ram i n i m u mo f3 0m i n u t e sp r o t e c t e d
from light and analyzed immediately by flow cytometry
utilizing an Epics XL-MCL BeckmanCoulter (The Wis-
tar Institute, Philadelphia, PA). Graphs represent average
fluorescence intensity or average percentage of cells
found in cell cycle phase over three consecutive inde-
pendent experiments.
Reverse Transcriptase-PCR and Real time (RT-PCR)
Total RNA from cell lines was extracted using the High
Pure RNA Isolation Kit (Roche) following the manufac-
turer’s instruction. cDNA was synthesized from 1 μgo f
total RNA by using random hexamers as primers and
m o l o n e ym u r i n el e u k e m i av i r u sr e v e r s et r a n s c r i p t a s e
(Invitrogen, Carlsbad, CA) according the manufacturer’s
protocol in a final volume of 20 μl. As a control for
genomic contamination a reverse transcription (RT)
reaction was carried out without the addition of the
reverse transcriptase (RT-). After cDNA synthesis, sam-
ples were diluted 1:10 and 4 μl was used in each real
Federico et al. Molecular Cancer 2010, 9:208
http://www.molecular-cancer.com/content/9/1/208
Page 11 of 14time polymerase chain reaction (real time PCR). cDNA
was amplified using species specific intragenic primers
for CCNA1[23], CCNA2, CCNB1, CCND3, CCNE1,
TP53 and GAPDH genes (Additional File 4). Real time
PCR was carried out utilizing SybrGreen Master Mix
(Roche, Basel, Switzerland) following the manufacturer’s
instructions in a final reaction volume of 10 μl. Reac-
tions were performed on a LightCycler 480 II (Roche
Diagnostics, Indianapolis, IN) with an initial denatura-
tion of 5 minutes at 95°C; 45 cycles of 10 seconds at 95°
C, 20 seconds at 60°C, and 10 seconds at 72°C where
fluorescence was acquired. Each sample was run in tri-
plicate and data was analyzed using the comparative Ct
method with GAPDH as the endogenous control and
control cells as the reference sample in each experiment.
Final data points represent the average fold change
respect to control (2
^-ΔΔCt) or expression levels respect
to GAPDH (2
^-ΔCt)o fa tl e a s tt h r e ec o n s e c u t i v ei n d e -
pendent experiments.
Alkaline Comet Assay
After appropriate drug treatments, cells were harvested
and analyzed utilizing the alkaline comet assay as pre-
viously described[41,42]. Briefly, cells were mixed in a
suspension of low melting point agarose and spread on
agarose-coated slides. Once the agarose solidified, slides
were incubated in lysis buffer followed by electrophor-
esis to allow migration of DNA and detection of DNA
damage. Cells were then stained with 1 μg/mL ethidium
bromide and analyzed using the fluorescence micro-
scope Olympus BX40 (Melville, NY) with a Spot-RT
digital camera and software (Webster, NY). At least 200
cells were evaluated per experimental point. Visual scor-
ing of comet images using fluorescence microscopy was
performed according to Norbury[43]. Briefly, each
nucleus is assigned a score from 0-4 depending on the
relative intensity of DNA fluorescence in the tail (0 =
no damage, 4 = >80% of DNA found in the tail) and the
final score is calculated as the average DNA damage
found in all cells counted from three consecutive inde-
pendent experiments. Statistical analysis was carried out
using a standard student’s t test.
Transient transfections
The human cyclin A1 IMAGE clone 5172478 (GenBank:
BC036346.1) was purchased from ATCC (MGC-34627)
transformed into DH5a heat-shock competent E. coli
cells and grown on LB agar plates or in broth with 100
μg/ml Ampicillin (Fisher) at 37°C. Plasmid DNA was
extracted using the Genopure Plasmid Midi Kit (Roche)
following manufacturer’s instructions then verified by
restriction enzyme digestion and gel electrophoresis.
HEK293FT cells were transiently transfected using a 6:2
ratio of Fugene HD (Roche) and plasmid DNA (2 μg)
following manufacturer’s protocol. Enhanced yellow
fluorescent protein (pEYFP) plasmid DNA was utilized
as a control for transfection efficiency at the same con-
centration. Cells were analyzed after 36 hours of trans-
fection by western blot and fluorescence microscopy to
confirm expression of transfected protein and then uti-
lized in experiments as described.
In vitro NHEJ assay
The in vitro NHEJ assay was performed on respectively
treated cell lysates as previously described[44] utilizing
120 μg of protein extract and 60 μg of purified BamHI
(Roche) digested pCI-neo plasmid DNA (Promega). A
reaction including the incubation of 20 μMW o r t m a n n i n
with whole cellular lysate for 15 minutes on ice before
the addition of digested plasmid DNA was included as a
negative control for NHEJ activity in each experiment.
After incubation samples were diluted 1:10, phenol
chloroform 25:24:1 (Fisher) extracted, and ethanol preci-
pitated overnight at 4°C. DNA was resuspended into 20
μl of Tris-EDTA buffer and 1 μl was utilized in each real
time PCR reaction. To detect plasmid re-ligation one set
of primers amplified an intact region of the plasmid to
act as the endogenous control, while a second set of pri-
mers bound both up-stream and down-stream of the
enzymatic cut site. Samples were run in triplicate with
each primer pair following the real-time PCR protocol
described above. Final results represent the average fold
change (2^
-ΔΔCt) in re-ligation respect to control, over
three consecutive independent experiments.
Microarray Analysis
T o t a lR N Aw a si s o l a t e db yT r i z o l( I n v i t r o g e n ) .F i f t e e n
μg of total RNA was converted to cDNA by using
Superscripts reverse transcriptase (Invitrogen), and T7-
oligo-d(T)24 (Geneset) as a primer. Second-strand
synthesis was performed using T4 DNA polymerase and
E.Coli DNA ligase and them blunt ended by T4 polynu-
cleotide kinase. cDNA was purified by phenol-chloro-
form extraction using phase lock gels (Brinkmann).
Then cDNAs were in vitro transcribed for 16 hours at
37°C by using the IVT Labelling Kit (Affymetrix) to pro-
duce biotinylated cRNA. Labelled cRNA was isolated by
using the RNeasy Mini Kit column (QIAGEN). Purified
cRNA was fragmented to 200-300 mer using a fragmen-
tation buffer. The quality of total RNA, cDNA synthesis,
cRNA amplification and cRNA fragmentation was
monitored by capillary electrophoresis (Bioanalizer 2100,
Agilent Technologies). Fifteen micrograms of fragmen-
ted cRNA was hybridised for 16 hours at 45°C with con-
stant rotation, using a human oligonucleotide array
U133 Plus 2.0 (Genechip, Affymetrix, Santa Clara, CA).
After hybridisation, chips were processed by using the
Affymetrix GeneChip Fluidic Station 450 (protocol
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din-conjugated phycoerythrin (SAPE)(Molecular Probes),
followed by amplification with a biotinylated anti-strep-
tavidin antibody (Vector Laboratories), and by a second
round of SAPE. Chips were scanned using a GeneChip
Scanner 3000 G7 (Affymetrix) enabled for High-Resolu-
tion Scanning. Images were extracted with the Gene-
Chip Operating Software (Affymetrix GCOS v1.4).
Quality control of microarray chips was performed
using the AffyQCReport software[45]. A comparable
quality between microarrays was demanded for all
microarrays within each experiment.
Microarray Statistical Analysis
The background subtraction and normalization of probe
set intensities was performed using the method of
Robust Multiarray Analysis (RMA) described by Irizarry
et al.[46]. To identify differentially expressed genes, gene
expression intensity was compared using a moderated t
test and a Bayes smoothing approach developed for a
low number of replicates[47]. To correct for the effect
of multiple testing, the false discovery rate, was esti-
mated from p-values derived from the moderated t test
statistics[48]. The analysis was performed using the
affylmGUI Graphical User Interface for the limma
microarray package[49].
Abbreviations Used
CDK: cyclin-dependent kinase; DDR: DNA damage
response; NHEJ: non-homologous end-joining; DSB:
double strand break; HR: homologous recombination;
NER: nucleotide excision repair; MMR: mismatch repair.
Additional material
Additional file 1: Western blot analysis of cyclin A1 protein
expression with and without the inclusion of phosphatase
inhibitors in lysis. Phosphatase inhibitor activity was confirmed by
probing for phosphorylated p130/Rb2 in comparison to full-length p130/
Rb2. After 24 hours of Doxorubicin treatment (750 nM and 2.5 μM),
cyclin A1 protein levels clearly augment in cells lysed with the inclusion
of phosphatase inhibitors, whereas the increase is not as notable in cells
lysed without the inclusion of phosphatase inhibitors.
Additional file 2: Flow cytometry analysis of cell cycle breakdown
after treatment. Flow cytometry analysis of cell cycle breakdown in
A549 cells treated for 24 hours with respective treatments of Doxorubicin
(750 nM or 2.5 μM) or 20 μM Roscovitine alone or in combination and
graph representing average cell cycle distributions from three
consecutive independent experiments.
Additional file 3: Drug induced changed in cyclin mRNA expression
levels. Expression levels respect to GAPDH (2^
-ΔCt), in mRNA of cyclin A1,
cyclin A2, cyclin B, cyclin D and cyclin E after 24 hours of treatment with
either increasing doses of Doxorubicin (250 nM to 5 μM) alone or in
combination with 20 μM Roscovitine.
Additional file 4: Table of gene specific primer sequences utilized in
this manuscript.
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